MedPath

Rehabilitation for women with breast cancer undergoing ajduvant chemotherapy.

Phase 4
Completed
Conditions
Cancer
Registration Number
PACTR202007730554581
Lead Sponsor
APERE
Brief Summary

Compared to controls, a significant increase in the WS (P < 0.01) and the WD (P < 0.01) accompanied by a significant decrease in resting rHR (P < 0.01), exercising HR6' (P < 0.01), [La]b (P < 0.05), HR6'/WS (P < 0.01) and [La]b/WS ratios (P < 0.01) was reported in the trained group. However, a significant decrease both in WD (P < 0.01) and WS (P < 0.01) has been observed in the controls. No significant difference was observed in resting HR, exercising HR6', [La]b, HR6'/WS, and [La]b/WS ratios were observed in the control group. A significant improvement was observed for RPE in training group (P < 0.05).

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
39
Inclusion Criteria

Women aged from 18 to 65 years.
- No known history of chronic respiratory, cardiac or neuromuscular disease.
- Diagnosed with non-metastatic breast cancer (stage y–IIIA).
- Women who have had a mastectomy and are in the process of adjuvant chemotherapy (postoperative).

Exclusion Criteria

- Hemoglobin concentration < 8 g/dL, platelet count < 20/nL.
- Obesity [body mass index (BMI) > 30].
- Malnutrition (BMI < 20).
- Treatment with high-dose corticoids (prednisone > 50 mg/day or equivalent dose of related agents).
- Chronic infection, neurological or muscular impairment.
- chronic diseases that could be exacerbated by exercise (coronary artery disease, chronic obstructive pulmonary
disease, osteoarthritis), skeletal metastases resulting in bone instability, or progressive disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.